SEARCH

SEARCH BY CITATION

References

  • 1
    Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 4348.
  • 2
    Ludwig J, McGill DB, Lindor KD. Review: non-alcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12: 398403.
  • 3
    Sheth SG, Gordon FD, Chopra S. Non-alcoholic steatohepatitis. Ann Intern Med 1997; 126: 13745.
  • 4
    Hui AY, Wong VWS, Chan HLY, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407413.
  • 5
    Wong VW, Chan HL, Hui AY, et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong-Kong Chinese. Aliment Pharmacol Ther 2004; 20: 459.
  • 6
    Fassio E, Alvarez E, Domínguez N, et al. Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 8206.
  • 7
    American Gastroenterological Association medical position statement: non-alcoholic fatty liver disease. American Gastroenterological Association. Gastroenterology 2002; 123: 17024.
  • 8
    Ramesh S, Sanval AJH. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 2005; 42 (Suppl. 1): S212.
  • 9
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11039.
  • 10
    Caldwell S, Oelsner D, Iezzoni J, Hespenheide E, Battle E, Driscoll C. Cryptogenic cirrhosis. Clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 6649.
  • 11
    Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2005; 23: 20715.
  • 12
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14139.
  • 13
    Medina J, Fernández-Salazar LI, García-Buey L, et al. Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. Diabetes Care 2004; 27: 205766.
  • 14
    Marchesini G, Natale R, Manini R, et al. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 179.
  • 15
    Oonawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis. Hepatology 2000; 32: 68991.
  • 16
    Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 1037.
  • 17
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidity obese subjects. J Hepatol 1991; 12: 2249.
  • 18
    Angulo P, Lindr KD. Treatment of non-alcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 818.
  • 19
    Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H: Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes; effect of sex and the LIPC promoter variant. Diabetes Care 2003; 26: 42732.
  • 20
    Clark LT. Treating dyslipemia with statins: the risk-benefit profile. Am Heart J 2003; 145: 3879.
  • 21
    Funatsu T, Suzuki K, Goto M, et al. Prolonged inhibition of cholesterol síntesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HEPg2 cells. Atherosclerosis 2001; 157: 10715.
  • 22
    Harlander JC, Kwo PY, Cummings OW. Atorvastatin for the treatment of NASH. Gastroenterology 2001; 120A: 544.
  • 23
    Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of non-alcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 7138.
  • 24
    Agrawal S, Bonkovsky HL. Management of non-alcoholic steatohepatitis. An analytic review. J Clin Gastroenterol 2002; 35: 25361.
  • 25
    Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 7480.
  • 26
    Joseph AE, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchyma liver disease. Clin Radiol 1991; 43: 2631.
  • 27
    Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 41533.
  • 28
    Gershovich OE, Lyman AE Jr. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy 2004; 24: 1504.
  • 29
    Perger L, Kohler M, Fattinger K, Flury R, Meier PJ. Fatal liver failure with atorvastatin. J Hepatol 2003; 39: 109597.